SCHEMBL5130792

SCHEMBL5130792

CCc1cccc(CN(C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)C(=O)c2c(-c3ccccc3)noc2C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
ALDH1A1 P00352 3/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SCD5 Q86SK9 1/20 0.40
GAA P10253 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GPBAR1 Q8TDU6 2/20 0.38
CTSD P07339 2/20 0.38
BACE1 P56817 2/20 0.38
CYP3A4 P08684 1/20 0.37
PTBP1 P26599 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125624 0.81 BACE1 (0.38) NPSR1SCD5L3MBTL1CTSDBACE1
SCHEMBL5124834 0.81 BACE1 (0.39) ALDH1A1MEN1KMT2ASCD5HPGD
SCHEMBL5120182 0.79 L3MBTL1 (0.37) NPSR1KMT2ASCD5L3MBTL1LMNA
SCHEMBL5130830 0.79 BACE1 (0.37) NPSR1SCD5L3MBTL1CTSDBACE1
SCHEMBL5579820 0.77 BACE1 (0.41) MEN1KMT2ACTSDBACE1
SCHEMBL5131158 0.77 ALDH1A1 (0.43) TSHRALDH1A1NPSR1MEN1KMT2A
SCHEMBL5129470 0.77 BACE1 (0.39) CTSDBACE1
SCHEMBL5129805 0.77 BACE1 (0.39) ALDH1A1NPSR1SCD5CTSDBACE1
SCHEMBL5130898 0.76 BACE1 (0.40) TSHRALDH1A1NPSR1MEN1KMT2A
SCHEMBL5126194 0.76 BACE1 (0.53) HPGDCTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 TSHR 4721/4885ALDH1A1 2178/4885HTT 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.